Suppr超能文献

在急性哮喘加重期,雾化吸入布地奈德单次2000微克剂量治疗与序贯重复500微克剂量治疗的比较。

Comparison of single 2000-microg dose treatment vs. sequential repeated-dose 500-microg treatments with nebulized budesonide in acute asthma exacerbations.

作者信息

Razi Cem Hasan, Turktas Ipek, Bakirtas Arzu

机构信息

Affiliations: Department of Pediatric Allergy and Asthma, Faculty of Medicine, Gazi University, Ankara, Turkey.

出版信息

Ann Allergy Asthma Immunol. 2008 Apr;100(4):370-6. doi: 10.1016/s1081-1206(10)60601-1.

Abstract

BACKGROUND

High repeated doses of inhaled corticosteroids (ICSs) are recognized as having a more rapid improvement of outcomes than a single dose of ICS in severe acute asthma. However, to our knowledge, there has been no direct comparison of the early effects of single or repeated administration of the same total dosage of ICS in children with moderate to severe exacerbations of asthma.

OBJECTIVE

To compare the efficacy of a single dose of 2000 microg of nebulized budesonide with 4 repeated doses of 500 microg of nebulized budesonide in 40 children with an acute asthma exacerbation.

METHODS

Randomized, double-blind, parallel study that compared the efficacy of 2000 microg of nebulized budesonide, administered in a single dose, with repeated doses (4 doses of 500 microg each) during the first 90 minutes in 40 children (mean [SD] age, 10.7 [2.4] years) with an acute asthma exacerbation that required treatment with an oral corticosteroid. Forced expiratory volume in 1 second, asthma attack score, and oxygen saturation were evaluated at 20, 40, 60, 90, 120, 180, and 240 minutes after initial treatment. Oral corticosteroids were given to all patients at 90 minutes.

RESULTS

There were no significant differences in forced expiratory volume in 1 second (P = .54) at any times between the groups. Also, asthma scores and oxygen saturation were not different in either group within 90 minutes (P = .51 and P = .64, respectively) and thereafter (P = .35 and P = .87, respectively).

CONCLUSION

The use of a single dose of nebulized budesonide is as effective as repeated administration of the same total dosage during the first 90 minutes before giving oral corticosteroids in children with moderate to severe exacerbations of asthma.

摘要

背景

在重度急性哮喘中,高重复剂量吸入性糖皮质激素(ICSs)被认为比单剂量ICS能更快改善预后。然而,据我们所知,对于中度至重度哮喘加重期儿童,尚未对相同总剂量的ICS单剂量或重复给药的早期效果进行直接比较。

目的

比较2000微克雾化布地奈德单剂量与4次重复剂量(每次500微克)雾化布地奈德对40例急性哮喘加重期儿童的疗效。

方法

一项随机、双盲、平行研究,比较了40例(平均[标准差]年龄为10.7[2.4]岁)需要口服糖皮质激素治疗的急性哮喘加重期儿童,在最初90分钟内单剂量给予2000微克雾化布地奈德与重复剂量(每次500微克,共4次)的疗效。在初始治疗后20、40、60、90、120、180和240分钟评估第1秒用力呼气量、哮喘发作评分和血氧饱和度。所有患者在90分钟时给予口服糖皮质激素。

结果

两组之间在任何时间的第1秒用力呼气量均无显著差异(P = 0.54)。此外,两组在90分钟内(分别为P = 0.51和P = 0.64)及之后(分别为P = 0.35和P = 0.87)的哮喘评分和血氧饱和度也无差异。

结论

对于中度至重度哮喘加重期儿童,在给予口服糖皮质激素前的最初90分钟内,单剂量雾化布地奈德的使用与相同总剂量的重复给药效果相同。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验